Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial
In infants with CHI, dasiglucagon significantly reduced the amount of IV glucose needed to maintain euglycemia compared with placebo. Dasiglucagon represents a promising treatment for the management of CHI.
Authors
- David M. Kendall (ORCID: https://orcid.org/0000-0003-1910-2587)
- Paul Thornton (ORCID: https://orcid.org/0000-0002-9706-5665)
- Sebastian Kummer (ORCID: https://orcid.org/0000-0002-4840-5256)
- Diva D. De León (ORCID: https://orcid.org/0000-0003-1225-8087)
- Jelena Ivkovic
- Indraneel Banerjee (ORCID: https://orcid.org/0000-0003-4280-7470)
- Stephen Birch (ORCID: https://orcid.org/0000-0002-1372-0440)
- Eva Bøge
Institutions
- Children's Hospital of Philadelphia (US)
- Düsseldorf University Hospital (DE)
- Cook Children's Medical Center (US)
- Zealand Pharma (Denmark) (DK)
- Royal Manchester Children's Hospital (GB)
- Heinrich Heine University Düsseldorf (DE)
- University of Pennsylvania (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1210/clinem/dgae818
- Citations
- 4
- Primary Topic
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Type
- article
- Field-Weighted Citation Impact
- 1.43